SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Data Collective IV GP, LLC

CIK 0001664974 · 270 UNIVERSITY AVENUE, PALO ALTO, CA, 94301 · 650-521-7814

Reported Value
$143M
Q2 2024
Positions
6
Filings on Record
19
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Data Collective IV GP, LLC reported $143M in U.S.-listed holdings across 6 positions for Q2 2024.

The portfolio is heavily concentrated: OKLO alone accounts for 41.1% of reported value.

Compared with Q1 2024, the fund opened 1 new position and exited 0.

Portfolio Metrics

Turnover
+25.8%
vs prior filed quarter
Largest Position
+41.1%
Oklo

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $741MQ4 ’21Q3 ’22: $127MQ4 ’22: $95MQ4 ’22Q1 ’23: $94MQ2 ’23: $135MQ2 ’23Q3 ’23: $106MQ4 ’23: $121MQ4 ’23Q1 ’24: $115MQ2 ’24: $143MQ2 ’24Q3 ’24: $163MQ4 ’24: $226MQ4 ’24Q1 ’25: $87MQ2 ’25: $130MQ2 ’25Q3 ’25: $68MQ4 ’25: $59MQ4 ’25Q1 ’26: $56Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 90.1%Other: 9.9%
  • Common Stock · 90.1% · $129M
  • Other · 9.9% · $14M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
OKLOOklo Inc.NEW+6.92M6.92M+$59M$59M
EVLVEvolv Technologies Holdings, Inc.HELD+09.68M$18M$25M
RXRXRecursion Pharmaceuticals, Inc.HELD+05.94M$15M$45M
Rocket Lab USA, Inc.HELD+02.93M+$2M$14M
Mind Medicine (MindMed) Inc.HELD+0100.3K$219,767$723,523
ROIVRoivant Sciences Ltd.HELD+03.9K+$116$40,959

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

6 positions
#IssuerClass% PortfolioValueShares
1OKLOOklo Inc.history →COM CL A41.08%$59M6.92M
2RXRXRecursion Pharmaceuticals, Inc.history →CL A31.23%$45M5.94M
3EVLVEvolv Technologies Holdings, Inc.history →COM CL A17.30%$25M9.68M
4Rocket Lab USA, Inc.COM9.85%$14M2.93M
5Mind Medicine (MindMed) Inc.COM NEW0.51%$723,523100.3K
6ROIVRoivant Sciences Ltd.SHS0.03%$40,9593.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$56M4May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$59M3Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$68M4Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$130M5Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$87M5May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$226M6Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$163M6Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$143M6Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$115M5May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$121M5Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$106M5Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$135M6Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$94M6May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$95M6Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$127M5Nov 14, 202213F-HRchanges · EDGAR ↗
Q4 2021$741M5Feb 14, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.